Many COVID-19 drugs, vaccines and tests depend on ‘the spike’. Roger Highfield, Science Director, describes why it is now the most important protein on the planet.
As we publish our new Access Framework, Director of Learning Susan Raikes shares how this document will guide our work on accessibility and ensure that it continues with energy and urgency.
Britain is planning the first human ‘challenge studies’, where people are deliberately infected with SARS-CoV-2. Roger Highfield, Science Director, explores the risks and benefits.
As new restrictions come into force in England, Sir Ian Blatchford, Director and Chief Executive of the Science Museum Group provides an update on the temporary closure of our five museums.
Deputy Director of the Science Museum Dr Julia Knights explores how we’re enhancing our biodiversity, a key part of our building back sustainably mantra at the Science Museum Group.
Curator of Art Collections Dr. Katy Barrett explores how working with artists in response to themes and objects in our collection can help to illuminate the role of science in our lives and identities. This post is part of our Open for All series.
In the latest in a series of online in-conversation events around the Science Museum Group’s value of being Open for All, Director & Chief Executive Sir Ian Blatchford talked to the Right Hon David Lammy MP about key themes from his latest book: Tribes: How Our Need to Belong Can Make or Break Society.
Tomorrow (28th July), Locomotion will be our first of our five museums to open its doors to visitors. Roger Highfield, Science Director, describes the science behind reopening.
Never before have so many of the world’s researchers focused so urgently on a single topic. Roger Highfield, Science Director, discusses how COVID-19 has highlighted the critical role of science in combating disease and how the greatest health challenge of a generation has changed science.
In the global race to curb the pandemic, scientists are testing a new kind of vaccine. Roger Highfield, Science Director, talks to key figures in the ‘David and Goliath’ race for a COVID-19 ‘RNA vaccine’.